Corcept Therapeutics
CORT • NASDAQ
Corcept Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Joseph K. Belanoff, with a market cap of $4.0B.
CEOJoseph K. Belanoff
Next Earnings
Upcoming earnings announcement for Corcept Therapeutics
Date
Monday, May 4, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.21
Revenue Estimate
$180.9M
Earnings History
Past 12 earnings reports for Corcept Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 24, 2026 | Q4 2025 | $0.20Est: $0.31 | -35.5% | $202.1MEst: $254.7M | -20.6% |  10-K |
| Nov 4, 2025 | Q3 2025 | $0.16Est: $0.15 | +6.7% | $207.6MEst: $218.8M | -5.1% | 10-Q |
| Jul 31, 2025 | Q2 2025 | $0.29Est: $0.20 | +45.0% | $194.4MEst: $201.3M | -3.4% | 10-Q |
| May 5, 2025 | Q1 2025 | $0.17Est: $0.14 | +21.4% | $157.2MEst: $177.9M | -11.6% | 10-Q |
| Feb 26, 2025 | Q4 2024 | $0.26Est: $0.37 | -29.7% | $181.9MEst: $195.7M | -7.1% | 10-K |
| Oct 30, 2024 | Q3 2024 | $0.41Est: $0.28 | +46.4% | $182.5MEst: $172.0M | +6.1% | 10-Q |
| Jul 29, 2024 | Q2 2024 | $0.32Est: $0.23 | +39.1% | $163.8MEst: $155.2M | +5.5% | 10-Q |
| May 1, 2024 | Q1 2024 | $0.25Est: $0.22 | +13.6% | $146.8MEst: $140.8M | +4.3% | 10-Q |
| Feb 15, 2024 | Q4 2023 | $0.28Est: $0.26 | +7.7% | $135.4MEst: $129.3M | +4.7% | 10-K |
| Nov 1, 2023 | Q3 2023 | $0.28Est: $0.21 | +33.3% | $123.6MEst: $119.3M | +3.6% | — |
| Aug 2, 2023 | Q2 2023 | $0.25Est: $0.15 | +66.7% | $117.7MEst: $109.7M | +7.3% | 10-Q |
| May 3, 2023 | Q1 2023 | $0.14Est: $0.19 | -26.3% | $105.7MEst: $104.9M | +0.7% | — |